189 results about "Pulmonary infection" patented technology

A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

The invention relates to an inhalation spray of antivirus medicines. The inhalation spray comprises the following components in percentage by mass of 0%-30% of antivirus activity agents, 0%-30% of auxiliary agents, 0%-30% of taste masking agents and the balance solvents, wherein the content of the antivirus activity agents and the content of the auxiliary agents are not 0% at the same time. Compared with the prior art, the inhalation spray disclosed by the application has the purpose that during outbreak period of epidemic corona viruses and other viruses, people do not need to occupy medicalresources in short supply and only need to inhale the antivirus medicines into respiratory tracts, medicine administration is accurately targeted, and the objective of preventing virus infection and propagation can be achieved; in addition, through united medication of the antivirus activity agents and the auxiliary agents, besides, various medicines are inhaled into the respiratory tract of a patient, synergistic treatment effects are generated, the viruses are eliminated, and serious respiratory tract and infection and serious pulmonary infection caused by the viruses can be treated; and chloroquine type antivirus medicines and macrocyclic antibiotics are inhaled through spraying for united medication, and the dosage of the medicines can be notably reduced, so that side effects of prolonged QT intervals, Tdp and sudden cardiac death caused by the medicines can be reduced.

In one aspect, the invention provides a stabilized lipid-based glycopeptide antibiotic composition and a process for producing the same. In another aspect, the invention provides methods for treating a bacterial pulmonary infection by administering to a subject in need thereof a therapeutically effective amount of the stabilized lipid-based glycopeptide antibiotic composition.

The present invention provides carbapenems to treat or prevent pulmonary infections, particularly in patients with cystic fibrosis, pneumonia, ventilator associated pneumonia, bronchitis or bronchiectstasis, pharmaceutical compositions of these carbapenems and methods of administering these carbapenems to treat or prevent pulmonary infections.

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or polysaccharides such as dextran, which also has surface active properties, or polymers such as polyethylene oxide (PEO) or biodegradable synthetic polymers which can be used to encapsulate or deliver the materials to be delivered. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

The invention discloses a prediction model for pulmonary infection after cardiac surgery and a construction method thereof. The method comprises the following steps: screening out evaluation indexes related to pulmonary infection after cardiac surgery from various clinical data of a cardiac surgery patient in a perioperative period; bringing the evaluation indexes into a Logistic regression modelto analyze, calculate and determine regression coefficients of risk factors of pulmonary infection after cardiac surgery; obtaining a risk score through the regression coefficient of each risk factor;and finally, combining the risk score with a pulmonary infection risk prediction function to calculate a pulmonary infection probability value, so that a risk prediction model based on a scoring system can be established. The prediction model disclosed by the invention is good in fitting, shows better risk prediction capability compared with the existing foreign model, can achieve the purpose ofearly screening postoperative pulmonary infection high-risk patients, and plays a role in early prevention, early discovery and early treatment, thereby reducing the incidence rate of postoperative pulmonary infection of the heart.

The invention provides a synthetic polypeptide composition for novel coronavirus immunodetection. The synthetic polypeptide composition contains four synthetic polypeptides, the synthetic polypeptidedisclosed by the invention can react with an antibody IgG/IgM of a novel coronavirus (2019-nCoV), does not react with other pulmonary infectious coronaviruses and the like, and does not react with serum of a normal person; the synthetic polypeptide disclosed by the invention is used for detecting a novel coronavirus (2019-nCoV) IgM/IgG antibody in serum, the sensitivity can reach 90% or above, thespecificity can reach 99% or above, and the polypeptide can be obtained through chemical synthesis, does not need to be recombined through a biotechnology, and is lower in cost, easier to obtain andconvenient to apply and popularize.

Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. The SP-D gene was targeted by homologous recombination in embryonic stem cells that were used to produce SP-D (−/−) mice. The SP-D (−/−) deficiency caused inflammation, increased oxidant production by isolated alveolar macrophages, abnormal surfactant structure and levels, and decreased SP-A expression. Therefore, disclosed is the SP-D (−/−) mouse as an excellent model for emphysema. Also included are models for testing emphysema therapies in the mouse model, methods for using SP-D protein or DNA as a treatment for emphysema and pulmonary infections, and diagnosis.

The invention discloses a method for detecting pathogenic bacteria of pulmonary infection by a visualized gene chip, comprising the following steps: S1 determining the spectrum of pathogenic bacteria of pulmonary infection based on clinical practice; S2 making the detection target according to the specific gene of the bacteria; S3 designing general primers and probes S4 chip preparation; S5 target gene amplification; S6 chip hybridization and washing; S7 gene chip visual detection; S8 optimization conditions, establishment of methods; S9 clinical verification; S10 comparison with bacterial culture; Chip detection. Beneficial effects of the present invention: realize rapid, sensitive, and high-throughput detection of important pathogenic microorganisms of common clinical respiratory infection flora, provide evidence for clinical disease diagnosis and anti-infection treatment of acute and severe respiratory infectious diseases; provide emergency, prevention and control Provide effective and efficient screening means and methods.

The invention relates to an image quantization method, computer equipment and a storage medium. The method comprises the following steps: segmenting a medical image of a to-be-detected object to obtain a first class segmented image and a second class segmented image, wherein the first class segmented image comprises at least one first region of interest, and the second type segmented image comprises second regions of interest corresponding to the first regions of interest; determining feature data corresponding to each second region of interest according to the at least one first region of interest and the second region of interest corresponding to each first region of interest, wherein the feature data is used for representing the distribution condition of each second region of interest;and determining a quantized value corresponding to the medical image according to the feature data corresponding to each second region of interest and the clinical feature data of the to-be-detected object, wherein the clinical feature data is data obtained after clinical detection is conducted on the to-be-detected object, and the quantized value is used for indicating the severity degree of pulmonary infection on the medical image. The method can improve the detection precision.

The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacter cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to Pseudomonas aeruginosa infection, for example in the treatment of pulmonary infection in cystic fibrosis patients, and represent a unique bactericidal medication that does not directly target the bacteria.

The invention discloses a multifunctional water bed. The multifunctional water bed comprises a sleeve bag, a water tank, a heater, a water pump, a nozzle group, a controller, a motor and a temperature probe, wherein the sleeve bag is longitudinally separated into a left sleeve bag and a right sleeve bag; the temperature probe comprises a water temperature probe and a body temperature probe; a water discharging hole of the water tank is connected with the heater through a filter; the heater is connected with an inlet of the water pump; the controller is connected with the motor and the heater; the motor is connected with the water pump; the controller is connected with the water temperature probe and the body temperature probe respectively. With the adoption of the multifunctional water bed, a function that a patient can turn over automatically is realized; meanwhile, an automatic back percussion function from bottom to top and from inside to outside of a patient after a thoracic surgery and pulmonary infection is also realized, so that the labor intensity of nurses is greatly alleviated; meanwhile, the multifunctional water bed is a cooling water bed for a patient with high fever and is a heat-conducting treatment water bed, and has an adjunctive treatment effect on the patient.

The invention discloses a glottis closed type tracheal catheter which comprises a tracheal catheter body, an air bag, an inflation valve and an inflation tube. A tracheal catheter interface and a tracheal catheter opening are formed in the two ends of the tracheal catheter body, the air bag is arranged nearby the tracheal catheter opening, the inflation tube is connected with the air bag, and the inflation valve controls on and off of the inflation tube. The glottis closed type tracheal catheter further comprises an expansion body, a water filling port and a water filling tube, wherein the expansion body is located at the position corresponding to the tracheal catheter body arranged into the glottis and is located on the outer side of the tube wall of the tracheal catheter and encloses the tube wall for one circle, the water filling tube is arranged on the side wall of the tracheal catheter body, one end of the water filling tube is connected with the expansion body, and the other end of the water filling tube is connected with the water filling port. The expansion body is arranged on the side wall of the tracheal catheter at the glottis, completely closes the glottis and prevents pharynx oralis secreta and gastroesophageal reflux from flowing into the glottis, and accordingly pulmonary infection, bronchial blockage and pulmonary atelectasis caused by descending of the pharynx oralis secreta and the gastroesophageal reflux are completely eradicated.